Meet the Team

Prevalence of Otalgia in
Patients with Temporo-mandibular Disorders

Patient Satisfaction 18 months After a Two-day Quadruple Therapy for Helicobacter Pylori

The Prevalence of Hepatitis B Carrier State

Total Quality Management for Turkish Primary Care Current Status and Suggestions

Vaccination Practice in Saudi Arabia: Is it Safe?

Change in Medical Students’ Opinions and Attitudes Towards Mental Illness

First Annual International Primary Care Conference-Abu Dhabi-UAE

Announcement of the Second Course of the MEAMA

Launch of 'World CME'

Antibiotic Sensitivity Profile of Common Bacterial Pathogens in Dubai
– A study of 107 cases

Women's Health Week in Rawalpindi, Pakistan

Middle East Academey for Medicine of Aging First Course

Pan Arab Congress for Evidence Based Medicine

Childhood Emergencies


Dr Abdulrazak Abyad
Editorial office:
Abyad Medical Center & Middle East Longevity Institute
Azmi Street, Abdo Center,
PO BOX 618
Tripoli, Lebanon

Phone: (961) 6-443684
Fax:     (961) 6-443685


Lesley Pocock
medi+WORLD International
572 Burwood Road,
Hawthorn 3122
: lesleypocock


Patient Satisfaction 18 months after a two-day quadruple therapy for helicobacter pylori eradication


Serpil AYDIN, MD, Assistant Professor, Adnan Menderes University, School of Medicine, Department of Family Medicine, Aydin, Turkey

Tankut KOSEOGLU, MD, Vice Chief, Department of Gastroenterology, Numune Research and Practice Hospital, Ankara, Turkey

Canan AGALAR, MD, Associate Professor, Kirikkale University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Kirikkale, Turkey


Serpil AYDIN
Mimar Sinan Mah, Sinan 4 Sok, No: 39, Dus Bahceleri Sitesi 09100 AYDIN, TURKEY

Phone: 0090 256 219 6181
Fax: 0090 256 214 6495
Email: serpilden@yahoo.com

This study was presented as a poster during the 2nd International Meeting on Antimicrobial Chemotherapy in clinical practice, in Italy, November 2001.

Date of submission: May 30, 2005


Objectives: Because the Helicobacter pylori (Hp) infection has been the most seen infection in the world, many research studies have been conducted to find an effective therapy regimen for eradication. Long-term regimens are being replaced by short term regimens as the long-term therapies cause more side effects and patient adjustment is not easy. Our aim was to determine the efficacy of a short-term therapy regimen and patient satisfaction by conducting a telephone survey 18 months after completion of the therapy regimen.

Materials and Methods: The patients with upper gastrointestinal system complaints who had presented to the gastroenterology day clinic in Ankara Numune Hospital were chosen for this study. They were evaluated, taking into account their historical, physical, laboratory, endoscopic, and histopathological findings. Patients who were found with Helicobacter pylori, but had no other symptoms or disorders, were given a two-day amoxicillin, ornidazole, and tribismuthsubcitrate therapy after a five-day lansoprazole therapy. The evaluation was repeated one month after the regimen. In addition, a telephone survey was conducted 18 months after eradication, and the patients whose upper gastrointestinal system complaints were completely eradicated were asked if they had any additional upper gastrointestinal system complaints during this 18-month interval.

Results: We applied the eradication therapy to 36 people. Complete eradication was obtained in 31 of the 36 patients. For the follow up telephone survey, we could not reach five of the patients due to changes in their address and/or telephone numbers; 15 patients indicated that they had not taken any drug; and 12 patients had no complaints during this 18-month period. Six patients received H2 receptor blocker irregularly, and five patients had taken our regimen once again on their own. All of the patients reached during the 18-month follow-up stated that they were satisfied with the therapy.

Conclusion: Our regimen appears to relieve symptoms for a long time and it is considered to be effective from our patients' viewpoints.

Key Words: helicobacter pylori; patient satisfaction; eradication therapy; telephone survey


Because the Helicobacter pylori (Hp) infection has been the most seen infection in the world, many research studies have been conducted to find an effective therapy regimen for eradication. Long-term regimens are being replaced by short term regimens because the long-term therapies have been found to cause more side effects and drug adjustment of patients is more difficult.
In developing countries like Turkey, Hp infection is more common (1). Because of the difficulties of drug maladjustment of patients, ineffective antibiotics, and common usage of antibiotics, it becomes much more difficult to eradicate Hp in developing countries. The effectiveness of a therapy can be shown not only by the eradication and side effect rate, but also by patient satisfaction.
In this study, we aimed to determine (a) an effective short-term therapy regimen that can be used by a developing country and (b) patient satisfaction with our therapy by following up with a telephone survey 18 months after eradication.


We chose patients with upper gastrointestinal system complaints, who had sought treatment at gastroenterology day clinics at the Ankara Numune Research and Practice Hospital during the period of December 1998-July 1999. In our study, we accepted patients who had been cured by earlier treatment, but who still had some complaints. We also accepted patients, who repeated their earlier treatments once more. After getting information about the study, oral informed consent was taken for each patient and they were assessed physically, clinically, and through laboratory findings. We only accepted patients, who had no other systemic symptoms or disorders. Any drugs they had been taking were stopped at least 15 days before the endoscopic assessment.


They were subjected to endoscopy after a 12-hour period without food. Before the examination, endotracheal Jetocaine was applied for 4 minutes. A Pentax FG29X flexible gastroscope was used. During the endoscopy, at least two specimens were taken from the antrum, corpus and fundus of the stomach. Biopsy specimens were taken for histological and urease tests, and within a half hour, those biopsy specimens, which were placed in a 70% alcohol solution, reached the pathology laboratory The biopsy specimens were painted with a Hemotoxylene- Eosine strain. One month after the therapy, all of these applications were repeated.

We applied a regimen consisting of a five-day-therapy of lansoprasole (30mg bid), a two-day-therapy of tribismuthsubsitrate (300mg qid), amoxicilin (1gram bid), and ornidazole (500mg bid) with lansoprasole. The patients were reassessed one month after treatment. A telephone survey was conducted at the 18th month after eradication and patients, who were treated successfully, were called 18 months after the treatment and asked if they had upper gastrointestinal system complaints after our treatment and if they had been retreated.


42 patients were enrolled in this study. Four patients indicated that they felt fine and did not need to repeat the endoscopic examination. Three patients had stopped the regimen because of side effects. Eradication was successful in 31 out of 35 patients (88.61%). Ulcers were seen in 11 (31.43%) patients, whose upper gastrointestinal system complaints had been completely eradicated after the therapy (eradication rate was 100%). In non-ulcer patients, the eradication rate for their upper gastrointestinal system complaints was 83.33% (20/24 patients). Table 1 shows the distribution of patients.

All the patients reported that their complaints were improved after the therapy.

Eighteen months after the therapy, 31 patients were called again to determine both the effectiveness of our therapy and patient satisfaction. We were able to reach 26 patients. Among those, 18 had no complaints and had not required additional treatment. Eight patients stated that they had the same upper gastrointestinal system complaints and only two of them reported that these were the same as they had prior to the treatment and because of this they needed to use the same drugs again once (Table 2). Only five of the 26 patients needed to use drugs again (Table 3) and two of them stated that they had the same complaints after they underwent surgery for other reasons and parenteral H2 receptor blocker were prescribed for them. The remaining three patients reported that they used the same regimen once more and after the second application they had no complaint.


Since discovery of Hp, many research studies have been conducted to detect its connection with chronic gastritis, duodenal ulcer, gastric ulcer, and adenocarcinoma (2,3,4). These observations have led researchers to conduct therapeutic investigations. Although the Hp microorganism is sensitive to antibiotics invitro, it is too difficult to eradicate in vivo.

As Hp is a true pathogen, there is an increasing inclination in the world to treat all Hp positive patients(5). Many therapy regimens have been tried. Among these, the eradication rates of monotherapies vary from 0 to 44%, whereas combined therapies have eradication rates from 33 to 94%(6,7). Although the two-week-triple therapy regimen is the most accepted, patients experience side effects, which is the major disadvantage. Nowadays, researchers try to find new therapy regimens with fewer side effects and ones that do not affect the patient's ability to think and speak clearly.

Amoxicillin, bismuth, and ornidazole are found effective in different combinations. By adding PPI, an antiasidic environment is provided, and bactericidal effectiveness is increased. Lansoprazole has 4 to 10 times more antihelicobacteric effect and performs acid suppression more quickly. When given two times daily, the 24-hour medium gastric pH increased. Furthermore, it relieves symptoms more quickly than omeprazole. It also reduces the risk of gastrointestinal bleeding(8,9).

In a 7-day-therapy regimen, eradication rates are greater than 90%(10). De Boer et al, recommend that there is no need to continue. In these regimens and in the quadruple regimens, side effect rates are 2.8%. Houben et al, make a comparison of these regimens and find that the eradication rate of bismuth-dependence after one or two weeks was less than 80% (11). In another study, a four-day quadruple regimen rate is 94% in a well-developed country (12). Our eradication rate was lower, and we thought that the main reason is that in developing countries infection and bacterial resistance are higher than in developed countries. In another study that was held in Italy, a two-day-quadruple therapy regimen is applied, and the eradication rate is 84% (13). It is much closer to our results and more successful in ulcer patients, as in our study.

Also there are some limitations of our study. We searched if our patients were satisfied with the therapy rather than the absence of Hp at the 18th month. Further investigations in this field should be done to determine the existence of Hp a long period of time after a therapy regimen.


Our treatment for eradicating Hp, especially in patients who have ulcers, is beneficial for both the patient and society(14). We recommend that all patients, who have a history similar to our patients, should be identified for Hp and treated.

As the main goal of the therapy of peptic ulcer disease is to eradicate Hp which will decrease the recurrence rate of ulcers (15), we think that we reached this goal by this regimen.

Our results at the eighteenth month supported our first results. Our study shows that our regimen was an effective one also from the viewpoint of the patients. Our regimen appears to relieve symptoms for a long time so it can be considered as a successful treatment plan. We suggest that short-term treatment is effective, causes less side effects, and results in more coherent and satisfied patients.

Table 1. Clinical Diagnosis of Patients in whom Helicobacter could be eradicated
Diagnosis n %
Ulcer 11 (11) 35.5
20 (24) 64.5
Sum 31 (35) 100

Table 2. Existence of complaints of patients who could be reached by telephone survey
Complaint existence during the 18 months Female
Male Sum
  n % n % n %
Exists 5 31.2 3 30 8 30.8
None 11 68.8 7 70 18 69.2
Sum 16 100 10 100 26 100

Table 3. Drug use of patients during the 18 months
Complaint existence during the 18 months Female
Male Sum
  n % n % n %
Yes 3
20 2 18 5 38
No 13 80 8 82 21 62
Sum 15 100 11 100 26 100


We acknowledge Janice O. Vantrease for her grammatical review.


1. Bani-Hani KE, Hammouri SM. Prevalence of Helicobacter pylori in Northern Jordan. Endoscopy based study. Saudi Medical Journal 2001; Vol. 22 (10): 843-847
2. Dixon MF, Sobala GM. Gastritis and duodenitis: The histopathologic spectrum. Eur J Gastroenterol Hepatol 1992; 4: 17-23
3. Feldman M, Cryer B, Mcarthur KE, Lee E. Relationship between severity of H. pylori(HP) gastritis and gastric acid-pepsin secretion in man. Gastroent 1996; 110: A 106 (abstract)

Sipponen P, Riihela M, Hyvarinen H, Seppala K. Chronic nonatrophic('superficial') gastritis increases the risk of gastric carsinoma. Scand J Gastroent 1994; 29: 336-40

5. Van Zanten V, Sender JO, Flook N, Chiba N, Armstrong D, Barkin A. An evidence-based approach to the management of uninvestigated dyspepsia in the era of H.pylori. CMAJ, 2000(S);162(12): pS3 (abstract)
6. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 1: 1233-5
7. 7- De Boer WA. Treatment of Helicobacter pylori infection. J Clin Gastroent 1994; 19: 347-50
8. Langtry HD, Wilde MI. Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473-500

8. Langtry HD, Wilde MI. Lansoprazole: An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473-500
9. Colin-Jones DG. Safety of lansoprazole. Br J Clin Pract 1994;73: 58-66
10. de Boer WA, Driessen WMM, Potters VPJ, Tytgat GNJ. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 1993-7
11. Houben MHMG, van de Beek D, Hensen EF, de Craen AJM, van't Hoff BWM, Tytgat GNJ. Helicobacter pylori eradication therapy in the Netherlands. Scand J Gastroenterol 1999;suppl 230:17-22
12. De Boer WA, Driessen WMM, Tytgat NJ. Only four days quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 633-638
13. Tucci A, Poli L, Paparo GF, Bocus P, TogUgani T, Mazzoni C, Orcioni GF, Agosti R, Grigioni WF, Sottili S, Caletti G. Weekend therapy for the treatment of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 737-742
14. De Boer WA, Tytgat GNJ. Treatment of Helicobacter pylori infection. BMJ, 2000; 722631-5
15. Bani-Hani KE. The current status of Helicobacter pylori. Saudi Medical Journal 2002; Vol. 23 (4): 379-383